Mode
Text Size
Log in / Sign up
N/A N=504

Protecta Smart Analysis Register

Patients With an Indication for an ICD Implantation According to the Guidelines

Enrolled (actual)
504
Serious AEs
Results posted
Nov 2018
Primary outcome: Primary: Analysis of Change of Episodes Inappropriately Treated by Shock Therapy Due to Smart Shock™ Technology. — 94.9 % of episodes wo shock due to SmartShock

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Primary completion
Jan 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Analysis of Change of Episodes Inappropriately Treated by Shock Therapy Due to Smart Shock™ Technology.
94.9
SECONDARY
Number of Patients With All Smart Shock Algorithms Are Programmed on
300
SECONDARY
Percentage of Patients, Without Shock Delivery Due to Smart Shock Technology
15.3
SECONDARY
Analysis of the Number of Patients With Primary Preventive Indication for an ICD That Develop VF Episodes.
15
SECONDARY
Number of Patients That Developed AT/AF
117
SECONDARY
Analysis of the Proportion of Patients in Which ICD Parameters Remain on Nominal Programming.
421
SECONDARY
Analysis of the Positive Predictive Value of the Investigated ICD Oversensing Algorithms
100

Summary

ProSA is a prospective, non-randomized, multicenter, observational study investigating the utilization and effectiveness of the Smart Shock™ algorithm in ICD patients treated with a Protecta™, Protecta™ XT or any equivalent following product.

Eligibility Criteria

Inclusion Criteria

  • patients implanted with an Implantable Cardioverter Defibrillator (ICD) with the smart shock algorithm (Protecta™, Protecta™ XT or any equivalent following product)
  • written informed consent

Exclusion Criteria

  • patients with life expectancy less than 24 months
  • patients younger than 18 years
  • pregnant or breast feeding women
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01714921). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search